Press Releases
Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany
Yakult Honsha files Initial Submission for Marketing Authorisation of Debiopharm´s Oxaliplatin in Japan
Dyax Corp. and Debiopharm S.A. report positive Results from Phase IIa Clinical Trial with DX-890 (EPI-hNE4) in Children with Cystic…
ELOXATIN™ submitted in the United States and in Europe for the adjuvant treatment of patients with colon cancer
Eloxatin™ (oxaliplatin for injection) approved in the United States for the 1st line treatment of metastatic colorectal cancer
ELOXATIN® is becoming a cornerstone therapy for the treatment of metastatic colorectal cancer in Europe
Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA – Cystic Fibrosis designation
Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of…